Opthea (NASDAQ:OPT – Free Report) had its price target decreased by Oppenheimer from $31.00 to $16.00 in a report issued on Wednesday, MarketBeat reports. Oppenheimer currently has an outperform rating on the stock. Separately, HC Wainwright reiterated a buy rating and set a $14.00 target price on shares of Opthea in a research report on […]
HC Wainwright restated their buy rating on shares of Opthea (NASDAQ:OPT – Free Report) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $14.00 target price on the stock. Separately, EF Hutton Acquisition Co. I started coverage on Opthea in a report on Monday, April 17th. They set a […]
Opthea Limited (NASDAQ:OPT – Free Report) – Investment analysts at SVB Leerink issued their FY2028 earnings per share estimates for Opthea in a report released on Sunday, July 23rd. SVB Leerink analyst M. Goodman expects that the company will earn $4.25 per share for the year. The consensus estimate for Opthea’s current full-year earnings is […]
Opthea (NASDAQ:OPT – Free Report) and Angion Biomedica (NASDAQ:ANGN – Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Valuation & Earnings This table compares Opthea and Angion Biomedica’s […]